Tessera Therapeutics
PrivateLast Round
Grant
Mar 23, 2026
Total Funding Raised
$631.3M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Tessera Therapeutics is a biotechnology company that develops gene writing technology to facilitate permanent modifications to the human genome for therapeutic purposes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tessera Therapeutics Comparables
Compare Tessera Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Prime Medicine | 86% | |
| Beam Therapeutics | 81% | |
| Arbor Biotechnologies | 81% | |
Tessera Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 23, 2026 | ||||
| Strategic | Dec 18, 2024 | ||||
| Series C | Apr 19, 2022 | ||||
| Series B | Jan 12, 2021 | ||||
| Seed | Jul 7, 2020 |
Key People
Founding team and executive leadership
Tessera Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SoftBank Investment Advisers | Series C, Series B |
| Altitude Life Science Ventures | Series C, Series B |
| Cormorant Asset Management | Series C |
| Longevity Vision Fund | Series C |
| SALT | Series C |
| ARTIS Ventures | Series C |
| SoftBank Group | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 23, 2026
$41.3M raised in grant funding.
- Mar 23, 2026
Developing curative in vivo genetic treatment for sickle cell disease.
Tessera Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Tessera Therapeutics's valuation, stock price, and market status.